缺血性心肌病急性左心衰竭经重组人脑利钠肽治疗的临床效果

苏春生

（陕西省汉中职业技术学院附属医院内二科，陕西 汉中，723000）

浏览次数：99次 下载次数：384次

摘要：

目的 探讨在缺血性心肌病急性左心衰竭患者治疗中，给予重组人脑利钠肽rhBNP治疗的效果。方法 选取2011年2月至2016年2月我院收治的380例缺血性急性左心衰竭患者作为研究对象，将其分为观察组与对照组，每组190例。对照组 患者给予常规药物治疗，包括血管扩张剂、洋地黄类药、利尿剂及β-受体阻滞剂等；观察组在常规治疗的基础上加用rhB-NP。两组患者在治疗前、后进行心脏彩超检查、脑钠肽测定，比较各指标水平。结果 治疗后，两组患者的LVEF、LVEDD及NT-proBNP水平均优于治疗前。观察组的LVEF水平明显高于对照组；观察组的LVEDD及NT-proBNP水平明显低于对照组，差异具有统计学意义（P<0.05）。观察组的有效率为96.3%，明显高于对照组的79.5%（P<0.05）。结论 在急性左心衰竭治疗中给予rhBNP，可明显改善患者的临床症状，治疗效果较好，值得临床推广。

关键词：缺血性心肌病；急性左心衰竭；重组人脑利钠肽

中图分类号：R541.6文献标志码：A文章编号：2096-1413(2017)06-0017-02

The clinical effect of recombinant human brain natriuretic peptide in the treatment of

ischemic cardiomyopathy with acute left heart failure
SU Chun-sheng
(the Second Department of Internal Medicine, the Affiliated Hospital of Hanzhong Vocational and Technical College,

Hanzhong 723000, China)

ABSTRACT: Objective To investigate the clinical effect of rhBNP in the treatment of ischemic cardiomyopathy with acute left heart failure. Methods Three hundred and eighty cases of patients with ischemic cardiomyopathy with acute left heart failure admitted in our hospital from February 2011 to February 2016 were selected and divided into observation group and control group, with 190 cases in each group. The control group received routine therapy, such as vasodilator, tigitalis drugs, diuretics and β-blocker, while the observation group accepted rhBNP on the basis of routine therapy. All the patients received echocardiography, brain natriuretic peptide text before and after treatment, the levels of clinical indexes of the two groups were compared. Results After treatment, the levels of LVEF、LVEDD and NT-proBNP of the two groups were better than those before treatment; the level of LVEF of the observation group was higher than that of the control group, the levels of LVEDD and NT-proBNP were lower than those of the control group, the differences were statistically significant (P<0.05). The total effective rate of the observation group was 96.3%, which was higher than 79.5% of the control group (P<0.05).Conclusion The rhBNP in the treatment of ischemic cardiomyopathy with acute left heart failure can effectively improve the clinical symptoms of the patients, and it has significant clinical effect. It is worthy of clinical promotion.
KEYWORDS: ischemic cardiomyopathy; acute left heart failure; recombinant human brain natriuretic peptide

参考文献：
[1] 李浩,秦灵芝.重组人脑利钠肽治疗缺血性心肌病急性左心衰竭疗效观察[J].河北医科大学学报,2014(6):676-678.
[2] 凌永红.重组人脑利钠肽治疗缺血性心肌病伴急性心力衰竭的疗效观察[J].临床合理用药杂志,2014,8(6):50-51.
[3] 吴炎,蒲红.重组人脑利钠肽治疗缺血性心肌病患者急性心衰的短期疗效观察[J].世界临床药物,2012,33(4):215-217.
[4] 何勇,谢喜仁.早期应用重组人脑利钠肽治疗急性左心衰竭的临床研究[J].中外医学研究,2014,7(5):64-65.
[5] 母雪飞,赵昕.重组人脑利钠肽对急性心肌梗死经皮冠状动脉介入治疗术后并发急性左心衰竭患者的临床观察[J].中国介入心脏病学 杂志,2015,20(11):39-41.
[6] 杨睿,葛慧敏.重组人脑利钠肽治疗缺血性心肌病心力衰竭的疗效分析[J].河南医学研究,2015,33(1):89-90.